

Tn903, pUC4K Remnants
KanR (Tn903)
pUC19
pPJV7563
3759 bp
Tn903, pUC4K Remnants
pUC19 MCS
PolyA Site 1
rGlob pA
Unknown
HBVenh
CMV Pro
BglII
NheI
CMV Exon1/2
CDS Insertion sites
Bam/Bgl fusion
ATG-Nhe
Rat Ins IntA
5'-UTR of HBV pre-S2

FIG. 1



10
20
Q T L N F D L L K L A G D V E S N P G * P FMDV 2A
- - E G R G S L L T C G D V E E N P G * P TAV 2A
H Y A G Y F A D L L I H D I E T N P G * P EMCV 2A
Q C T N Y A L L K L A G D V E S N P G * P ERAV 2A
- A T N F S L L K Q A G D V E E N P G * P PTV 2A

FIG. 2

5'UAACGUUACUGGCCGAAGCCGCUUGGAAUAAGGCCGGUGUGCGUUUGUCUAU
AUGUUAUUUUCCACCAUAUUGCCGUCUUUUGGCAAUGUGAGGGCCCGGAAACCU
GGCCCUGUCUUCUUGACGAGCAUUCCUAGGGGUCUUUCCCCUCUCGCCAAAGG
AAUGCAAGGUCUGUUGAAUGUCGUGAAGGAAGCAGUUCCUCUGGAAGCUUCUU
GAAGACAAACAACGUCUGUAGCGACCCUUUGCAGGCAGCGGAACCCCCCACCUG
GCGACAGGUGCCUCUGCGGCCAAAAGCCACGUGUAUAAGAUACACCUGCAAAGG
CGGCACAACCCCAGUGCCACGUUGUGAGUUGGAUAGUUGUGGAAAGAGUCAAAU
GGCUCUCCUCAAGCGUAUUCAACAAGGGGCUGAAGGAUGCCCAGAAGGUACCCC
AUUGUAUGGGAUCUGAUCUGGGGCCUCGGUGCACAUGCUUUACAUGUGUUUAG
UCGAGGUUAAAAAACGUCUAGGCCCCCCGAACCACGGGGACGUGGUUUUCCUUU
GAAAAACACGAUGAUAAU*AUGGCCACAACCAUG3'

FIG. 3



100
80
60
40
20
0
% survival
0
20
40
60
80
100
120
days post tumor implant
Vehicle+ control
Sutent+ control
Sutent+ aCTLA4
Sutent+ vaccine
Sutent+ vaccine+aCTLA4
Log-rank
P=0.003
Log-rank
P=0.11

FIG. 4



IFNγ spots / 1e5 CD8 cells
400
300
200
100
0
control mAb
CpG
a-CD40 mAb

FIG. 5



*
*
*
3.0x10^5
2.0x10^5
1.0x10^5
0
total cytokine+ CD8 T cells
PMED
PMED+CpG
Single cytokine
Double cytokines
Triple cytokines

FIG. 6



*
*
4.0x10^4
3.0x10^4
2.0x10^4
1.0x10^4
0
total cytokine+ CD4 T cells
PMED
PMED+CpG
Single cytokine
Double cytokines
Triple cytokines

FIG. 7



8.0x10⁴
6.0x10⁴
4.0x10⁴
2.0x10⁴
0
total cytokine+ CD8 T cells
*
PMED with IgG
PMED with aCD40
single cytokine
double cytokines
triple cytokines

FIG. 8



8.0x10^4
6.0x10^4
4.0x10^4
2.0x10^4
0
total cytokine+ CD4 T cells
*
*
*
PMED with IgG
PMED with aCD40
single cytokine
double cytokines
triple cytokines

FIG. 9



Percent survival
100
80
60
40
20
0
0
50
100
days
control vaccine (n=10)
cancer vaccine (n=10)
Sutent 5mg/kg + control vaccine (n=8)
Sutent 5mg/kg + cancer vaccine (n=10)

FIG. 10



CMV Enh
tef pro
dp
PSA
T2A
PSCA
F2A
PSMA
SV40 pA
LITR
C68 genome
RITR
PacI
ΔE1
ΔE3
PacI
pCC1BAC-LCyeast-TRP Trunc

FIG. 11




FIG. 12



(-) control AdV
AdC68-733
AdC68-734
AdC68-735
AdC68-809
30
20
15
160
110
80
60
20
15
10
PSA
PSMA
PSCA

FIG. 13